Zhou Ping
Chairman

Doctor of Medicine, Professor, Chief Physician and Doctoral Supervisor at Tongji Hospital of Huazhong University of Science and Technology, selected for the National Ten Thousand Talents Program, and recipient of the Science and Technology Innovation Talent Program of the Ministry of Science and Technology of China and the 3551 Optics Valley Talent Program in Wuhan. Engaged in organ transplantation and general surgery clinical practice for 35 years, creating and maintaining multiple transplantation records in Asia and China. Previously worked as an assistant professor at the University of Chicago in the United States, and participated in multiple cutting-edge international research projects.

With over 20 years of research and development experience, he has profound expertise in the field of bioartificial liver. As early as 1997, he participated in the early development of ELAD bioartificial liver in the United States. In 2006, he collaborated with Okayama University Hospital in Japan to develop immortalized human derived liver cell bioartificial liver. In 2010, he independently developed the HepAssis2 bioartificial liver system, and its industrialization began in 2013.

He is an editorial board member and reviewer for over ten well-known professional journals, including the Chinese Journal of Organ Transplantation, American Journal of Immunology, and American Journal of Transplantation. Received 5 National Natural Science Foundation projects domestically and led multiple national level scientific research projects in the United States. Published over 100 papers in international authoritative professional journals, including Nature Medicine, JNCI, Genes and Development, JCI, etc. We have over 40 national patents and 10 international patents.

The current chairman of the company is responsible for making decisions on the company's development strategy planning, financing plans, annual business plans, and major projects and daily business processes.